Early cancer detection Leverage their AI-driven epigenetic imprinting platform to position as a diagnostic aid for indeterminate tumor biopsies, targeting pathology labs and hospital systems seeking faster definitive cancer diagnoses.

LOI diagnostic expansion Capitalize on the recent development of Loss of Imprinting measurement to offer a first-in-class assay, creating upsell opportunities with cancer risk assessment and monitoring programs for oncology centers.

Strategic partnerships Target collaborations with major pharmaceutical and biotech players (e.g., Merck) and regional innovation hubs to scale through co-development, validation studies, and regional distribution deals in high-potential markets like China.

Regulatory and validation posture Position the company as a rapid-pathway provider for clinically validated tests, emphasizing their reported up-to-one-week turnaround to accelerate lab adoption, with a focus on payer alignment and reimbursement strategies.

Scale & markets Highlight potential for multi-cancer screening across up to 13 cancer types, creating a scalable product roadmap and cross-selling opportunities to labs, cancer centers, and screening programs seeking comprehensive genomic-epigenomic solutions.